Trial Profile
A randomised controlled trial to evaluate whether a short course of once weekly risedronate prevents bone loss following high-dose steroid therapy for an acute exacerbation of inflammatory bowel disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Risedronic acid (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Biomarker; Therapeutic Use
- 27 Sep 2011 New trial record